Alternative Complement Pathway Inhibition by Lampalizumab: Analysis of Data From Chroma and Spectri Phase III Clinical Trials

PURPOSE: Lampalizumab, an antigen-binding fragment of a humanized monoclonal antibody directed against complement factor D (CFD), is designed to treat geographic atrophy (GA) secondary to age-related macular degeneration. Given the lack of clinical efficacy observed in patients with GA in the phase...

Descripción completa

Detalles Bibliográficos
Autores principales: Edmonds, Rose, Steffen, Verena, Honigberg, Lee A., Chang, Michael C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10205501/
https://www.ncbi.nlm.nih.gov/pubmed/37228694
http://dx.doi.org/10.1016/j.xops.2023.100286

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10205501/
https://www.ncbi.nlm.nih.gov/pubmed/37228694
http://dx.doi.org/10.1016/j.xops.2023.100286

Ejemplares similares